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ABSTRAK
Mengelola glomerulonefritis primer atau bahkan sekunder tetap menjadi tantangan bagi banyak nefrologis. 
Pada glomerulosklerosis fokal segmental primer (FSGS) dengan proteinuria berat, blokade sistem renin 
aldosterone dan prednisolon oral dosis tinggi merupakan andalan pengobatan. Obat imunosupresif lainnya 
seperti Cyclophosphamide, Cyclosporine A dan Mycophenolate Mofetil (MMF) dibenarkan jika remisi 
lengkap tidak tercapai. Penulis mengilustrasikan kasus pria berusia 21 tahun dengan FSGS primer yang sulit 
mencapai remisi meskipun menggunakan steroid dosis tinggi dan Cyclophosphamide oral. Pasien juga tidak 
responsif terhadap kombinasi MMF dan Cyclosporine A (CSA) dan bahkan selama terapi ia mengembangkan 
steroid dan toksisitas CSA yang signifikan. Pasien dirujuk dengan sindrom nefrotik berat dan cedera ginjal 
akut yang membutuhkan hemodialisis akut. Meskipun diberikan kembali prednisolon dosis tinggi, total 2,4g 
Cyclophosphamide intravena, dan MMF, namun gagal mencapai remisi. Kemudian diberikan Rituximab intravena 
500mg/minggu untuk 4 dosis dan mampu mencapai remisi selama 1 tahun. Pasien mengalami kekambuhan dan 
pemberian kedua Rituximab 500mg/mingguan 6 dosis untuk mencapai remisi. Kasus ini menunjukkan kesulitan 
dalam mengelola FSGS steroid refrakter dan kami menemukan bahwa Rituximab terbukti bermanfaat dalam 
hal ini untuk menginduksi remisi.
Kata kunci: refraktori glomerulo-sklerosis, intravena rituximab.
ABSTRACT
Managing primary or even secondary glomerulonephritis remains a challenge to many nephrologists. In 
primary focal segmental glomerulosclerosis (FSGS) with heavy proteinuria, renin aldosterone system blockade 
and high dose of oral prednisolone is the mainstay of treatment. Other immunosuppressive medications like 
Cyclophosphamide, Cyclosporine A and Mycophenolate Mofetil (MMF) are warranted if a complete remission 
is not achieved.  We illustrate a case of 21 year old gentleman with primary FSGS that was difficult to achieve 
remission despite on high dose steroid and oral Cyclophosphamide. He was also not responsive to a combination 
of MMF and Cyclosporine A (CSA) and even throughout the therapy he developed significant steroid and 
CSA toxicity. He presented to our center with severe nephrotic syndrome and acute kidney injury requiring 
acute haemodialysis. Despite re-challenged him again on high dose prednisolone, total of 2.4g of intravenous 
Cyclophosphamide, and MMF, he failed to achieve remission. He was subsequently given intravenous Rituximab 
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500mg/weekly for 4 doses and able to attained remission for 1 year. He relapsed again and a second course of 
Rituximab 500mg/weekly for 6 doses were given to attain remission. This case demonstrates the difficulty in 
managing refractory steroid dependent FSGS and we found that Rituximab is proven beneficial in this case to 
induce remission.
Key words: refractory focal segmental glomerulosclerosis, intravenous Rituximab.
INTRODUCTION
Focal segmental glomerulosclerosis (FSGS) 
is a kidney disease causing proteinuria due to 
glomerular sclerosis which may leads to renal 
dysfunction or end stage renal failure (ESRF). 
FSGS can be classified as primary where 
no underlying cause has been found for the 
development of focal podocytes injury. Whereas, 
secondary FSGS is considered if the podocytes 
injury can be explained due to other causes such 
as  obesity, human immune virus infection, IgA 
nephropathy, vasculitis, lupus nephritis, drugs 
including heroin and interferon treatment, reflux 
nephropathy or sickle cell anemia.1 It is important 
to distinguish between primary and secondary 
FSGS as treatment approach is different.2
The Kidney Disease Improving Global 
Outcomes (KDIGO) guideline stated that oral 
high dose prednisolone is the immunosuppressant 
of choice for primary FSGS presented with 
nephrotic range proteinuria.3 The major 
prognostic indicator of renal survival is the initial 
response of the proteinuria to steroid therapy. 
Thus, remission of proteinuria is the ultimate 
goal in primary FSGS. A complete remission that 
is defined as reduction of proteinuria to less than 
200 to 300 mg/day, meanwhile partial remission 
can be defined as 50% or greater reduction in 
proteinuria to a level that is <3.5 g/day. Any 
patients relapse while steroid is being tapered, or 
within two months of stopping steroid therapy, 
they are considered steroid dependent. Patients 
with little or no reduction in urine protein 
excretion after 12 to 16 weeks of treatment are 
considered steroid resistant.3
Most patients with steroid dependent FSGS 
required long-term low-dose corticosteroid 
therapy along with either cyclophosphamide 
(CYC), cyclosporine A (CSA), Mycophenolate 
Mofetil (MMF) or Rituximab to maintain clinical 
remission.4-6 Angiotensin-converting enzyme 
inhibitor (ACEi) or Angiotensin-II receptor 
blockers (ARB) is indicated in patients with 
FSGS but the results on proteinuria is variable.7,8 
Nevertheless, both ACEi and ARB has been 
proven to retard the progression of chronic 
kidney disease to end stage kidney disease by 
reducing proteinuria and maintaining blood 
pressure.9,10 However, care must be taken to 
avoid symptomatic hypotension and increment of 
creatinine. Fluid overload should be treated with 
diuretics especially loop diuretics. Combination 
of loop diuretic with thiazide can be considered 
in refractory fluid overload. Salt intake to 6 
gram/day (2g of sodium) is essential to prevent 
fluid retention. It is always important to balance 
the side effects and the benefits of medications 
given to the patient. Here we illustrate a case of 
a refractory primary FSGS and the management 
approach in our centre.
CASE ILLUSTRATION
A 21 year old gentleman presented 3 years 
ago at a state hospital with nephrotic syndrome. 
His creatinine was 105 µmol/L (eGFR of 82 
ml/min/1.73m2), serum albumin of 15g/L, urine 
protein creatinine index (PCI) 0.93g/mmol 
creatinine.  A diagnosis of FSGS; non-otherwise 
specified (NOS) type was confirmed on renal 
biopsy and screening tests for secondary causes 
were all negative. He was initiated on high dose 
oral prednisolone (1mg/kg/day; 60mg/kg/day). 
He achieved complete remission after 1 month 
of high dose oral prednisolone with urine PCI 
reduced to 0.01g /mmol creatinine, resolution of 
body edema and preservation of renal function. 
Unfortunately, he relapsed while on tapering 
dose of oral prednisolone to 5mg daily at 6 months 
of therapy. A second course of oral prednisolone 
at (1mg/kg/day; 60mg/day) was then restarted. 
He developed multiple relapses while attempting 
to taper down the prednisolone. Despite added on 
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oral cyclophosphamide 125 mg daily (2.5 mg/kg/
day) for 2 months his disease remains difficult to 
control. He was then switched to oral cyclosporine 
A (CSA) 100 mg twice a day for 9 months. 
Oral MMF was started following cyclosporine 
toxicity with worsening of renal profile and gum 
hypertrophy which later resolved after withdrawal 
of the drug. He was kept on MMF 1g twice daily 
with maintaining high dose prednisolone at 60mg 
daily as every attempt to taper down his oral 
prednisolone, his urine protein will rose further. 
His urine PCI was remained at 0.40 g/mmol 
creatinine after his second relapsed.
He presented to our center with overt 
nephrotic syndrome and oliguric acute renal 
failure while he was on prednisolone 60mg/day 
and MMF 1gm twice daily. His serum albumin 
was 19 g/L, urine PCI was 2.90 g/mmol creatinine, 
serum creatinine of 980 mmol/L and urea of 20 
mmol/L. An ultrasound of the renal system was 
normal. Magnetic resonance angiography and 
magnetic resonance venography showed no 
evidence of renal artery stenosis or renal vein 
thrombosis. Renal biopsy was consistent with 
acute tubular necrosis with underlying focal 
segmental glomerulosclerosis – non-otherwise 
specified (NOS) type (Figure 1). He was treated 
with intravenous methylprednisolone 250 mg 
daily for 3 days followed by 50 mg daily then 
oral prednisolone 60mg daily.
He required temporary haemodialysis. He 
was then given intravenous cyclophosphamide 
(IV CYC) 2 weekly for 5 doses with total 
cumulative dose of 2.4 gram; subsequently 
he was then continued with MMF 1 gm twice 
daily. His urine protein reduced to 1.2 g/day 
after 5 months and his kidney function was 
completely recovered. Despite of compliance 
to his immunosuppressive treatment consist of 
prednisolone 35mg daily and MMF 1gm twice 
daily, he never achieved complete remission with 
urine PCI remains between 0.12 to 0.14 g/ mmol 
creatinine (Figure 2). Calcineurin inhibitor was 
not started at that time as he was just recovered 
from acute kidney injury with past history of 
failure to CSA.
Unfortunately, his high dose steroid therapy 
caused him to develop steroid induced diabetes 
mellitus requiring oral antidiabetic medication. 
Due to refractory FSGS, we decided for 4 doses 
of intravenous (IV) Rituximab 500mg/weekly. 
He responded well to the IV Rituximab and in 
clinical remission (urine PCI less than 0.03 g/ 
mmol creatinine, serum albumin of  37 g/L) 
for 1 year (Figure 2) and subsequently was 
maintained with MMF 1 g twice daily, oral 
prednisolone 10mg daily and perindopril 4mg 
daily then gradually optimized to 8 mg daily. 
His blood pressure ranging between 110-120 
mmHg/70- 80 mmHg.
A year later, he relapsed again with urine 
PCI increased to 1.70 g/mmol creatinine. 
Serum albumin dropped from 38 to 19 g/L. His 
corticosteroid dose was increased again to 60mg/
day. MMF dose was maintained at 1gm twice a 
day and restarted on CSA 50mg twice a day at 
1mg/kg/day. He was compliant to his treatment 
and already had signs of steroid toxicity such 
as exogenous Cushing’s; abdominal striae, and 
proximal myopathy. Decision was made to give 
him another prolong course of IV Rituximab 
comprised of 6 doses of 500 mg/weekly while 
his oral prednisolone was tapered to prevent 
further side effects. He responded very well and 
reduction of his urine protein after the second 
dose of IV Rituximab (Figure 2). We strongly 
believe that the effect on proteinuria reduction 
was driven by Rituximab rather than the addition 
of low dose of CSA itself.
Figure 1. Renal biopsy showed capsular adhesion (upper 
left) and mesangial expansion and proliferation (upper 
right). Tubules were dilated and exhibiting cytoplasmic 
vacuolations and blebbing of apical membrane (bottom 
left) with eeosinophilic proteinaceous casts within lumen 
(bottom right).
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In view of previous history of CSA toxicity 
(acute kidney injury, gum hypertrophy) at 2 mg/
kg/day, his CSA is optimized at a slower pace. 
Now, he is maintained with oral prednisolone 
10mg daily, MMF 1g BD and CSA 100mg 
twice daily (triple therapy). He is also double 
anti-proteinuric medications; perindopril 8mg 
daily, telmisartan 80mg daily and atorvastatin 
20 mg at night. His signs of steroid toxicity 
such as proximal myopathy and abdominal 
striae have resolved upon tapering down his 
oral prednisolone and his diabetic control is well 
manage with dietary control only.
DISCUSSION
Primary FSGS is a glomerular disease with 
variable clinical course. According to KDIGO 
guideline, treatment with corticosteroid and 
other immunosuppressant are only indicated 
in primary FSGS associated with nephrotic 
syndrome.3 Relapse after clinical remission 
is very common in primary FSGS. It is a 
challenge for nephrologist in managing refractory 
FSGS complicated with steroid toxicity as we 
experienced in this particular case.
Steroid is the mainstay of treatment for 
primary FSGS. Pulse with high dose of IV 
methylprednisolone is associated with favorable 
clinical outcome in active refractory primary 
FSGS. However, prolonged steroid treatment 
can cause significant side effects such as diabetes 
mellitus and exogenous cushing. Thus, for our 
patient, the ultimate aim was to optimize the 
steroid sparing immunosuppressant’s to render his 
primary FSGS to remissions and at the same time 
to taper down his steroid to prevent worsening 
of his steroid toxicity. Cyclophosphamide (CYC) 
is an alkylating agent which is recommended 
as a steroid sparing immunosuppressant for 
steroid responsive primary FSGS.11 CYC is 
administered for 8 to 12 weeks. The combination 
of CYC with steroid is associated with a longer 
remission period in steroid dependent primary 
FSGS. Treatment more than 12 weeks shows no 
beneficial clinical outcome.11 Furthermore, bone 
marrow suppression, hemorrhagic cystitis and 
gonadal toxicity are well known complications 
of prolong CYC therapy.
CSA is a calcineurin inhibitor (CNI) which 
may be beneficial in primary refractory FSGS 
unresponsive to CYC.12 It can also serve as first 
line therapy in primary FSGS where steroid 
treatment is contraindicated or intolerance to 
high dose. CSA is associated with 50% reduction 
in relapse rate and as good as CYC.13 Remission 
may take 3–6 months following treatment. 
Relapses do occur after withdrawal of CSA.12 
However, prolong CSA treatment, perhaps up 
to one year or longer after remission is achieved 
associated with low risk of relapse.14 Side effects 
of CSA include tremor, hypertrichosis, gum 
hypertrophy, hypertension, and nephrotoxicity. 
Figure 2. Relationship between serum Creatinine and urine PCI
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Risk of nephropathy increases if high-dose CSA 
(more than 5.5 mg/kg/d) is given, patient has 
pre-existing chronic renal failure with eGFR 
less than 60 ml/min per 1.73 m2 and present of 
tubule-interstitial fibrosis in renal biopsy.14 Thus, 
CNI should be avoided if eGFR is less than 30 
mL/min/1.73 m2. Tacrolimus (TAC) may serve 
as alternative CNI in cases of CSA-resistant 
or CSA-dependent FSGS.15 The cosmetic 
side effects such as hypertrichosis and gum 
hypertrophy are not seen with TAC. Thus, it is 
preferred in patient who cosmetic side effect is 
a major concern. However, the incidences of 
other risk factors such as nephropathy, tremor, 
and diabetes mellitus are the same for both TAC 
and CSA.14,15
MMF acts via inhibition of T cell and B 
cell. It is an alternative agent in primary FSGS 
when CNI is contraindicated or refractory 
and developed complications following CNI 
therapy.16 MMF is indicated in patients with 
partial response to steroid or serves as steroid 
sparing immunosuppressant in cases of steroid 
toxicity. In our patients; MMF was started 
following CSA induced nephropathy. MMF 
is not inferior to CNI in preventing relapses 
but only if given at high doses.16 MMF has 
relative fewer side effects compare to CNI. 
Some of the common MMF side effects include 
gastrointestinal symptoms such as diarrhea, 
abdominal pain and hyperlipidemia.
As illustrated in our case, he received the 
conventional therapy as per recommendation 
in KDIGO guideline. Unfortunately, not only 
refractory to therapy namely high dose steroid, 
CYC (oral or IV), combination of prednisolone 
with CSA as well as MMF, he also developed 
severe side effects such as nephrotoxicity and 
gum hypertrophy with CSA and also Cushing’s 
syndrome and diabetes due to the high dose of 
steroid. Therefore Rituximab was utilized in this 
case as adjunctive treatment to render him into 
remission. Rituximab therapy here is reserved 
after attempts with steroid, CNI, or MMF have 
failed to induce remission.
Rituximab is a chimeric monoclonal antibody 
that inhibits CD20-mediated B lymphocytes. 
Rituximab has protective effect on podocytes. 
Several reports have demonstrated successful 
treatment of Rituximab in refractory steroid 
dependent primary FSGS.17-19 Therapy for 
FSGS with IV Rituximab has been reported 
in some case reports in recurrent nephrotic 
syndrome after renal transplantation in paediatric 
population.17,20 Nevertheless, the potential 
usefulness of rituximab in adult FSGS has been 
varies in term of doses, regime and responses.21 
Utilization of Rituximab as a treatment in adult 
refractory FSGS remains debatable on what will 
be the optimal dose and how frequent it should 
be.
Soluble urokinase-type plasminogen 
activator receptor (suPAR) levels were increased 
in FSGS as evidence by two large cohorts; 
the FSGS Clinical Trial (FSGS CT) and the 
PodoNet European FSGS consortium.22 suPAR 
is the cleaved molecule derived from urokinase 
type plasminogen activator receptor (uPAR) 
and uPAR is a membrane-bound protein 
linked to glycosylphosphatidylinositol (GPI) 
present on podocytes. suPAR may trigger the 
podocytopathy in the majority of patients with 
primary FSGS via activation of podocyte αvβ3 
integrin. suPAR act as permeability factor that 
stimulates the podocyte αvβ 3 integrin signaling 
pathway causing proteinuria. Rituximab inhibit 
suPAR-podocyte αvβ3 integrin signaling via 
modulation of sphingomyelin phosphodiesterase 
acid-like 3b.23 Unfortunately, in this case we 
were unable to measure the suPAR as it is not 
available in our center.
Removal of this circulating factor by 
plasmapheresis is an option as it can reduce 
proteinuria and induced clinical remission. 
However, the efficacy of plasmapheresis in 
recurrent FSGS is quite variable. The average 
respond rate ranging 50% to 60%.24 The 
respond rate is dependent on the absolute 
level of the circulating permeability factor. 
Relapse can occur during rapid tapering of 
plasmapheresis sessions and usually requires 
prolonged reinstitution of the plasmapheresis 
sessions.  Hence, individualization of treatment 
schedule depending on clinical response has 
been proposed. In this case, we opted to treat 
him with IV Rituximab and in view of his 
good response, plasmapheresis was not done. 
Plasmapheresis perhaps should be considered 
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if he does relapse again in the future. In those 
treated with plasmapheresis and responding, 
treatment should be continued until proteinuria 
has been reliably suppressed to below 0.5 g/day.
The development of anti-ri tuximab 
autoantibodies may be of concern in this case 
following repeated Rituximab infusion.25,26 
Hence, the presence of anti-ri tuximab 
autoantibodies is suspicion for cases of severe 
infusion reaction and if B cell depletion is 
not observed following Rituximab therapy. A 
close relation between B-cell depletion and 
clinical remission of refractory FSGS has been 
reported.25 The typical rituximab regimen is 
usually given at 2–6 doses (375 mg/m2/dose), 
administer once every 1 to 2 weeks.
Rituximab was well tolerated by our patient 
and allowed us to taper dose of prednisolone 
to prevent worsening of his steroid toxicity. 
He achieved full remission after 1st 4 cycles 
of rituximab with 500mg/week dose. Though 
he relapsed a year later, a second course of 
rituximab 500mg/week for 6 weeks also resulted 
in gradual clinical remission without the need 
for high dose prednisolone. Currently, his 
treatment is directed to optimization of his triple 
immunosuppressive therapy and anti-proteinuric 
medications while ensuring minimal side effects 
to induced complete remission as our ultimate 
target.
CONCLUSION
The management of refractory primary FSGS 
as illustrated in this case remains a challenge 
for nephrologists. Steroid in combination with 
immunosuppressant such as CNI, CYC or 
MMF may induce partial if not total remission 
of proteinuria. Rituximab should be considered 
as an alternative treatment in severe refractory 
primary FSGS associated with treatment 
toxicities. This case report supports a generalized 
effectiveness of rituximab treatment in FSGS. 
More studies are necessary to characterize 
further the type of patients who have FSGS that 
could benefit from rituximab administration. 
The optimal dosage and frequency of rituximab 
in this disease remains a challenge. Although 
mechanistic effects of rituximab on the podocytes 
were clear and potential permeability factor has 
been identified, current evidence on the nature of 
this factor and on the pathogenesis of recurrent 
FSGS remains inconclusive.
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